LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.